Barclays
ZLAB icon

Barclays’s Zai Lab ZLAB Stock Holding History

Barclays’s Portfolio ZLAB Stock Details ZLAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$107K Buy
4,048
+3,756
+1,286% +$86.8K ﹤0.01% 4272
2026
Q2 		$5.55K Sell
292
-3,239
-92% -$64K ﹤0.01% 4766
2026
Q1 		$66.4K Buy
3,531
+3,530
+353,000% +$65.4K ﹤0.01% 4198
2025
Q4 		$18 Sell
1
-734
-100% -$17.2K ﹤0.01% 5150
2025
Q3 		$24.9K Sell
735
-6,803
-90% -$234K ﹤0.01% 4907
2025
Q2 		$264K Buy
7,538
+2,836
+60% +$93.2K ﹤0.01% 4112
2025
Q1 		$170K Buy
4,702
+1,000
+27% +$30.8K ﹤0.01% 4144
2024
Q4 		$97K Buy
3,702
+2,856
+338% +$79.3K ﹤0.01% 4599
2024
Q3 		$20.4K Sell
846
-4,172
-83% -$78.8K ﹤0.01% 4897
2024
Q2 		$87K Sell
5,018
-26,268
-84% -$462K ﹤0.01% 3972
2024
Q1 		$501K Buy
31,286
+30,686
+5,114% +$646K ﹤0.01% 3592
2023
Q4 		$16.4K Hold
600
– – ﹤0.01% 4927
2023
Q3 		$14.6K Hold
600
– – ﹤0.01% 4236
2023
Q2 		$16.6K Sell
600
-71,947
-99% -$2.35M ﹤0.01% 4163
2023
Q1 		$2.41M Buy
72,547
+18,147
+33% +$696K ﹤0.01% 2050
2022
Q4 		$1.67M Sell
54,400
-93,632
-63% -$2.95M ﹤0.01% 2383
2022
Q3 		$5.06M Sell
148,032
-114,384
-44% -$4.89M 0.01% 1154
2022
Q2 		$9.1M Buy
262,416
+127,930
+95% +$4.51M 0.01% 1052
2022
Q1 		$5.91M Buy
+134,486
New +$6.5M ﹤0.01% 1154
2020
Q3 		– Sell
-21,129
Closed -$1.74M – 5643
2020
Q2 		$1.74M Buy
21,129
+13,029
+161% +$881K ﹤0.01% 2256
2020
Q1 		$417K Buy
8,100
+4,605
+132% +$240K ﹤0.01% 3737
2019
Q4 		$145K Sell
3,495
-556
-14% -$20.5K ﹤0.01% 5258
2019
Q3 		$131K Buy
4,051
+3,372
+497% +$116K ﹤0.01% 5276
2019
Q2 		$23K Buy
+679
New +$20K ﹤0.01% 6384
2019
Q1 		– Sell
-2,790
Closed -$65K – 7379
2018
Q4 		$65K Buy
+2,790
New +$51.7K ﹤0.01% 5326

Other funds holding ZLAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Patient Square Capital
Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
WealthPlan Investment Management
WealthPlan Investment Management Omaha, Nebraska $2.07B AUM 21.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Barclays's ZLAB Position: Q3 2026 in Review

Barclays increased its Zai Lab (ZLAB) stake by 1,286% in Q3 2026, buying an estimated $86.8K and bringing the position to 4,048 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #4272.

Barclays first reported a position in ZLAB in Q4 2018 and has held it in 25 quarters since. The position peaked at $9.1M in Q2 2022. 36 funds tracked by Wall St. Rank hold ZLAB as of Q3 2026.

  • Barclays held 4,048 shares of Zai Lab worth $107K as of Q3 2026.
  • Barclays bought 3,756 Zai Lab shares in Q3 2026, an estimated $86.8K.
  • Zai Lab made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4272 holding.
  • Barclays first reported a position in Zai Lab in Q4 2018 and has held it in 25 quarters since.
  • Barclays's Zai Lab position peaked at $9.1M in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Zai Lab as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.